A ring of RNA helps stem cells stay undecided
Original title: CircACVR2A(2-4) regulates stem cell pluripotency by uncoupling CDK-activating kinase functions.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done in animals, not people. Most findings at this stage never become treatments.
This was only done in lab cells and in mice.
The short version
Lab work found a ring-shaped RNA that keeps stem cells from picking a path too soon.
What was studied. Researchers used human stem cells in the lab and let them turn into five kinds of tissue. They then switched off certain ring-shaped RNAs to see what would change.
What they found. Switching off one ring RNA, called circACVR2A(2-4), made the stem cells stop acting like stem cells. The cells leaned toward becoming early nerve tissue instead. In mice, switching it off slowed nerve cells from moving in the growing brain. It also slowed glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary tumor growth in mice.
What this means, and what it doesn't
What it could mean: This points to a possible weak spot in glioblastoma: A glioma that is given grade 4. Grade 4 is the highest grade there is. The tumor grows fast. Treatment usually starts soon after it is found. It often means surgery, and then radiation and chemotherapy. See the glossary that drugs might one day aim at. Work like this helps scientists decide what to study next.
What it doesn't mean: This is early lab and mouse work. It is not a treatment and it is not a cure. No one has tested this in people. There is no drug for this today that a doctor can give you. It would take years of more study before this could reach patient care.
Source: PubMed, October 13, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.